Owira PM, Ojewole JA. The grapefruit: an old wine in a new glass? Metabolic and cardiovascular perspectives.
Cardiovasc J Afr. 2010 Sep-Oct;21(5):280-5. Review.
PubMed PMID: 20972517. [Free Full Text via PubMed.]
Noting that grapefruit is popular worldwide for its taste and nutritive value and also as a functional food with health benefits, researchers from the University of KwaZulu-Natal (Durban, South Africa) reviewed the literature about grapefruit, its interactions with drugs, and its effects on the metabolic syndrome and cardiovascular disease.
From the Conclusions:
“In the last 10 years, grapefruit has been a pharmacologoist’s nightmare, given its popularity and potential for interaction with many therapeutic drugs. To date, no clear guidelines have been put forward to protect vulnerable patients against the hazardous consequences of grapefruit–drug interactions. However, it is now emerging that apart from drug interactions, which have largely been attributed to furanocoumarins, flavonoids such as naringin and hesperidin could be playing more important roles in the prevention of diabetes and cardiovascular diseases. Attention has now shifted to investigating the molecular mechanisms by which these flavonoids exert their protective cardiovascular effects. In the coming years, basic and clinical research in cardiovascular pharmacology should be focused on grapefruit and its flavonoids and/or their chemical derivatives.”
Free full text is available via PubMed.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.